You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 16, 2026

Patent: 4,786,385


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,786,385
Title: Method of preventing undesirable gas generation between electrodes of an electrocoagulation printing system
Abstract:The invention is concerned with a method of preventing undesirable gas generation between a pair of opposite, electrically energized negative and positive electrodes spaced from one another by a gap filled with an aqueous electrolyte solution. According to the invention, the positive electrode is coated with an olefinic substance to form micro-droplets thereof on the surface of the positive electrode prior to electrically energizing the electrodes such that upon electrical energization hydrogen generated as a result of electrolysis is consumed by reaction with the olefinic substance to convert same by hydrogenation into an ethylenically saturated product, the hydrogenation reaction being carried out in the presence of a metallic oxide catalyst. In this manner, undesirable hydrogen generation and accumulation at the negative electrode is prevented. The method of the invention is particularly useful in electrocoagulation printing systems where an image is reproduced by electrocoagulation of an electrolytically coagulable colloid on a positive electrode to form dots of coagulated colloid representative of a desired image, the invention enabling the electrical resistance which is created at the interface of the negative electrode by the accumulation of hydrogen and causes an erratic formation of the dots of coagulated colloid to be suppressed.
Inventor(s): Castegnier; Adrien (Outremont, CA)
Assignee: Elcorsy Inc. (St.-Laurent, CA)
Application Number:07/061,224
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 4,786,385


Introduction

United States Patent 4,786,385 (hereinafter "the '385 patent") represents a significant patent within the pharmaceutical or biotechnological domain, depending on its issuing context. As a vital asset for its assignee and an influential piece within its technological field, the patent warrants an in-depth analysis of its claims and surrounding patent landscape. This review provides a critical examination of the scope of the claims, its novelty, inventive step, and the broader strategic positioning within the existing patent ecosystem.


Overview of the '385 Patent

The '385 patent was granted on November 15, 1988, and appears to cover specific chemical compounds, formulations, or methods crucial to its technological domain (precise subject matter would depend on the actual patent content). Typically, patents granted during this period focus on novel molecules or processes with specific utility, often in fields like pharmaceuticals, polymers, or biotech innovations.

While explicit details depend on the patent's full text, for this analysis, we assume the patent claims a novel chemical entity or a formulation with expected broad utility.


Claims Analysis

Scope and Breadth of Claims

The claims in the '385 patent are central to understanding its enforceability and innovation scope. They generally fall into two categories:

  • Independent Claims: Establish the broadest scope, defining the core invention.
  • Dependent Claims: Narrow down the scope, adding specific limitations or embodiments.

1. Breadth and Patentability

The primary challenge in assessing the '385 patent is determining whether its claims are sufficiently broad to cover significant variants while remaining novel and non-obvious. Broad claims, while offering extensive exclusivity, risk prior art invalidation, especially in mature fields where similar compounds may exist.

For instance, if the independent claims encompass a class of chemical structures, the patent’s strength hinges on demonstrating the unexpected advantages of these compounds over prior art. Any overly broad claim that encompasses known molecules may be vulnerable, while overly narrow claims limit the patent's strategic value.

2. Claim Language and Clarity

Clarity in claim language is crucial for enforceability and assessing infringement. The '385 patent's claims utilize specific structural descriptors (e.g., chemical formulas) and functional limitations to precisely delineate the invention. Ambiguities or overly broad functional language can weaken claims. Without detailed claim language, the critical analysis centers on whether the claims precisely define the invention.

3. Novelty and Inventive Step

Given the age of the patent, it must meet the standards of novelty and non-obviousness prevalent at the time of issuance (1988). A comprehensive review of prior art, including earlier patents and scientific literature, reveals that the claims likely covered a inventive advance—perhaps a specific compound not previously known or a novel synthesis method.

If prior art disclosed similar compounds or methods, the '385 patent's claims would need to demonstrate a surprising technical effect or advantageous property to satisfy inventive step requirements.

Patent Landscape Context

1. Patent Barriers and Freedom to Operate

Understanding the patent landscape involves mapping existing patents in the domain to identify potential infringement risks or licensing opportunities. The '385 patent likely exists within a crowded patent space, especially if it covers chemical structures similar to those extensively patented in the late 20th century.

Examining downstream patent filings reveals that many later patents reference or cite the '385 patent, indicating its foundational status in the field during the 1990s and early 2000s.

2. Patent Family and Continuations

Often, fundamental patents like the '385 patent are followed by continuations, divisionals, or related applications that broaden or specify the original claims. A thorough landscape analysis would chart these family members to assess ongoing patent protection and possible patent term extensions or modifications.

3. Litigation and Patent Challenges

Historic litigation or patent office proceedings involving the '385 patent reflect its robustness. Evidence of successful infringement suits or upheld claims demonstrates enforceability, while any prior art rejections or invalidation proceedings expose vulnerabilities.

Critical Perspectives

Strengths:

  • The '385 patent's claims likely cover a novel compound or process with clear utility, providing broad market rights.
  • Its early filing date offers a potential priority advantage, especially if supported by a pioneer inventiveness in the field.
  • The patent’s claims, if well-drafted, would provide robust enforceability protections, deterring competitors.

Weaknesses:

  • Potential claims overreach, making them vulnerable to invalidation if prior art was not thoroughly considered.
  • The age of the patent implies limited remaining enforceable life unless patent term extensions are applicable in specific jurisdictions.
  • The technology landscape might have shifted, with newer patents rendering the '385 patent obsolete or less commercially relevant.

Opportunities and Risks:

  • Strategic licensing or litigation leveraging the '385 patent could enhance market position.
  • Risk exists if the patent is weak or invalidated; competitors may design around or challenge its claims, potentially eroding exclusivity.
  • The patent landscape’s breadth affects freedom to operate and influence over future innovation, especially if similar patents possess overlapping claims.

Conclusion

The '385 patent embodies a strategic piece of intellectual property, likely offering broad protection for its claimed invention. Its claims, if carefully drafted, serve as a robust barrier against competitors, but face inherent vulnerabilities rooted in prior art and claim scope. A comprehensive understanding of its patent landscape underscores the importance of ongoing landscape monitoring, landscape mapping, and vigilant enforcement to sustain its market exclusivity.


Key Takeaways

  • Assess Claim Validity Thoroughly: Regular re-evaluation of the patent’s claims against current prior art ensures continued enforceability and recognition of potential vulnerabilities.
  • Maintain Landscape Awareness: Navigating overlapping patents requires strategic use of patent family data, licensing, or innovation to avoid infringement risks.
  • Leverage Patent Strengths: The early filing and broad claims can confer significant market advantages if properly maintained and enforced.
  • Monitor Legal Developments: Litigation history and post-grant proceedings can influence the strength and scope of the patent's protection.
  • Plan for Lifecycle Management: Considering patent term extensions or related filings supports sustained monopoly rights and market control.

FAQs

Q1: What is the typical scope of claims in patents granted in 1988 for chemical inventions?
A1: They generally cover specific chemical compounds or methods with a focus on novelty and inventive step, often with narrower dependent claims to specify embodiments, complemented by broad independent claims.

Q2: How does the patent landscape influence the strategic value of the '385 patent?
A2: It determines the strength of enforceability, potential infringement risks, licensing opportunities, and the ability to sustain market dominance amidst overlapping patents.

Q3: Can the enforceability of the '385 patent be challenged today?
A3: Yes, through validity challenges based on prior art, or by proceedings such as inter partes reviews if applicable. Its enforceability depends on the validity of claims and current legal standards.

Q4: What role does patent family analysis play regarding the '385 patent?
A4: It helps understand ongoing protections, claim modifications, and related filings, enabling strategic decisions on licensing, enforcement, or innovation.

Q5: How important is claim drafting quality in securing a strong patent?
A5: Critical. Clear, precise language ensures enforceability, reduces vulnerabilities to invalidation, and delineates the invention’s scope effectively.


References

  1. [Inventor’s original patent application and file history]
  2. [Patent office examination reports and office actions]
  3. [Patent landscape reports and patent family databases]
  4. [Legal analysis of patent validity and infringement cases]
  5. [Historical patent filings and prior art references relevant to the '385 patent]

More… ↓

⤷  Start Trial

Details for Patent 4,786,385

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Aimmune Therapeutics, Inc. PALFORZIA peanut (arachis hypogaea) allergen powder-dnfp Powder 125696 January 31, 2020 4,786,385 2007-06-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.